Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmacyclics LLC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years old
Histologically confirmed diagnosis of malignant gliomas that requires systemic antineoplastic treatment. Malignant glioma is defined as any of the following: Glioblastoma multiforme (GBM); Anaplastic astrocytoma (AA); Anaplastic oligodendroglioma; Anaplastic mixed glioma; Glioma not otherwise specified (except low-grade glioma)
ECOG performance status score of 0, 1, or 2
Each patient must sign a study-specific informed consent form
You may not be if
Laboratory values of:
Absolute neutrophil count \< 2000/µL
Platelet count \< 100,000/µL
AST or ALT \> 2 x the upper limit of normal (ULN)
Alkaline phosphatase \> 5 x ULN
Bilirubin \> 2 x ULN
Creatinine \> 2.0 mg/µL
and
Plan to use any additional cancer therapy (e.g., systemic, radiation, surgery) during the study period
Women who are pregnant or lactating
Clareo Health | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
